Abbott Settles Formula Plant Shutdown Case for $385 Million
Abbott will pay $385 million to settle claims tied to the shutdown of the biggest U.S. infant formula plant, the closure that emptied shelves across the country in 2022.
Abbott has agreed to a $385 million settlement over the closure of the largest baby formula plant in the United States, the shutdown that triggered nationwide infant formula shortages in 2022.
Abbott Laboratories (ABT) has agreed to pay $385 million to settle claims arising from the shutdown of the largest infant formula plant in the United States, the closure that drained store shelves and forced families to ration feedings through much of 2022.
The settlement, reported by STAT News, draws a line under one of the most disruptive consumer product failures of the decade — an episode that turned a manufacturing problem at a single facility into a national supply emergency, prompted federal airlifts of formula from overseas, and reshaped how regulators think about concentration in essential food manufacturing.
One plant, one product category, one country
The core of the 2022 crisis was structural rather than scientific. Infant formula in the United States is made at a small number of very large plants, and the one at the center of this settlement was the biggest of them. When it stopped producing, there was no equivalent capacity waiting to absorb the volume. Retail shelves emptied within weeks, and the shortage persisted far longer than the plant's own downtime because rebuilding inventory across a national distribution network takes months, not days.
That is what made the episode unusual. Most product recalls affect a lot, a batch, or a brand. This one affected an entire category of food for a population — newborns and infants — that has no substitute, no ability to wait, and in many cases specific medical formulations with no alternative supplier at all. Families dependent on specialty formulas for metabolic conditions were left with the fewest options of anyone.
The shortage also collided with the federal nutrition system. A large share of U.S. infant formula is purchased through the WIC program, which contracts with a single manufacturer per state. That design keeps prices down in normal times and concentrates risk catastrophically when the contracted supplier stops shipping. Households that had been steered toward one brand by their benefits found that brand was precisely the one that had disappeared.
What $385 million does and does not settle
A settlement of this size is a resolution of legal exposure, not an admission that closes every open question. It converts an unquantifiable liability — years of litigation with an unknown ceiling — into a single, budgetable number. For a company of Abbott's scale, that certainty is often worth more than the cash.
Investors read it that way on the day. Abbott shares traded at 103.10 as of 20:00 GMT on Monday, September 14, 2026, up 1.13% from the prior close of 101.95, with an intraday range of 102.57 to 104.44. That gain came against a weak tape: the S&P 500, tracked by SPY, was down 0.45% at $760.85, the Nasdaq 100 proxy QQQ was off 0.79% at $709.26, and the Dow 30 proxy DIA was down 0.25% at $524.49. On an illustrative basis, Abbott outpaced the broad market by roughly 1.58 percentage points on the session — the classic pattern for a defendant that has just capped a long-running overhang at a known figure.
What the settlement does not do is undo the operational lesson. The nutrition business that produced the plant's output remains a consumer-facing franchise where brand trust is the asset, and trust rebuilt after a shortage is not the same as trust never broken. Competitors that gained shelf space during 2022 did not all give it back.
The regulatory machinery that moved afterward
The 2022 shortage forced an uncomfortable review of how food safety oversight actually functions at scale. The central criticisms were about speed and information flow: how long it took for concerns about a single facility to translate into action, and how little visibility anyone — regulator, manufacturer, or retailer — had into what a single plant's closure would do to national supply.
The 2022 shortage forced an uncomfortable review of how food safety oversight actually functions at scale.
Out of that came a durable policy question that this settlement does not answer: whether the United States should tolerate a formula supply chain in which one facility going offline constitutes a national emergency. The candidate fixes are all expensive. Redundant capacity costs money to build and money to keep idle. Diversifying suppliers under WIC would raise program costs. Loosening import rules to admit European formula permanently would require harmonizing labeling and nutrition standards that were written to be different.
Each of those debates has moved at its own pace since 2022, and none of them is resolved by a check from one manufacturer. The settlement closes Abbott's legal chapter. The structural chapter belongs to policymakers.
What to watch from here
Three things are worth tracking. The first is how the settlement is accounted for — whether it lands as a discrete charge against a single period or is spread out, and what management says about the effect on the nutrition segment specifically. That is the clearest read on whether $385 million is a rounding item or a real dent in a business line.
The second is whether this resolution is comprehensive or partial. Large product liability matters frequently settle in tranches, with one group of claimants resolved while others litigate on. If further claims remain live, the overhang narrows rather than disappears, and the market's relief will prove premature.
The third is capacity. The most meaningful measure of whether the 2022 crisis produced change is not a settlement figure at all; it is how many U.S. plants can make infant formula today and how quickly any one of them could be replaced. Until that number moves, the same shutdown would produce the same shortage.
For now, the immediate story is straightforward. A shortage that put parents in the position of driving between counties looking for a can of formula has ended in a $385 million payment. Whether it also ended in a more resilient supply chain is a question the settlement leaves open.
Key facts
- Settlement amount: $385 million
- ABT share price: 103.10, +1.13%, as of 20:00 GMT, Sept 14, 2026
- Shortage year: 2022, following the plant's closure
- Market backdrop: S&P 500 (SPY) $760.85, down 0.45% on the day
Frequently asked questions
How much is Abbott paying in this settlement?
Abbott has agreed to a $385 million settlement tied to the closure of the largest infant formula manufacturing plant in the United States. The shutdown of that facility was the trigger for the nationwide formula supply shortages that ran through 2022, leaving parents unable to find product on retail shelves for months.
Why did one plant closure cause a national shortage?
U.S. infant formula is produced at a small number of very large facilities, and the plant involved was the biggest. When it stopped producing, there was no equivalent spare capacity to absorb the lost volume. Rebuilding national inventory then takes months beyond the plant's own downtime, which is why the shortage outlasted the closure itself.
How did Abbott shares react?
Abbott traded at 103.10 as of 20:00 GMT on September 14, 2026, up 1.13% from the prior close of 101.95, within an intraday range of 102.57 to 104.44. That came on a day when the S&P 500 proxy SPY fell 0.45% and the Nasdaq 100 proxy QQQ fell 0.79%.
Does the settlement mean the litigation is over?
A settlement resolves the claims it covers, but large product liability matters often settle in stages, with some claimant groups resolved while others continue to litigate. Until it is clear whether this agreement is comprehensive, investors should treat it as capping a known portion of exposure rather than eliminating all of it.
Who was hit hardest by the 2022 formula shortage?
Infants dependent on specialty medical formulas had the fewest alternatives, since those products often have no substitute supplier. Families using the federal WIC nutrition program were also heavily exposed, because WIC contracts with a single manufacturer per state, concentrating supply risk on one brand precisely when that brand became unavailable.
What would actually prevent a repeat?
The proposed fixes all carry cost: building redundant manufacturing capacity, diversifying suppliers under federal nutrition contracts, or permanently easing import rules so foreign formula can fill gaps. None is resolved by a financial settlement. The practical test is how many U.S. plants can make formula today and how fast any one could be replaced.
Sources
Photo: Gustavo Fring · Pexels Licence — source
